Stroke News and Research

RSS

A stroke is a medical emergency. Strokes happen when blood flow to your brain stops. Within minutes, brain cells begin to die. There are two kinds of stroke. The more common kind, called ischemic stroke, is caused by a blood clot that blocks or plugs a blood vessel in the brain. The other kind, called hemorrhagic stroke, is caused by a blood vessel that breaks and bleeds into the brain. "Mini-strokes" or transient ischemic attacks (TIAs), occur when the blood supply to the brain is briefly interrupted.

Advanced ovarian cancer: Avastin-chemotherapy combination followed by Avastin alone improves PFS

Genentech, Inc., a wholly owned member of the Roche Group, today announced that a Phase III study showed the combination of Avastin® (bevacizumab) and chemotherapy followed by maintenance use of Avastin alone increased the time women with previously untreated advanced ovarian cancer lived without the disease worsening (progression-free survival or PFS), compared to chemotherapy alone. A preliminary assessment of safety noted adverse events previously observed in pivotal trials of Avastin.

25 Feb 2010

JVC offers treatment for vascular diseases and thrombotic disorders under one roof

The new Jefferson Vascular Center at Thomas Jefferson University Hospital offers an integrated, multidisciplinary approach to the diagnosis, management and treatment of vascular diseases (diseases of blood vessels) and thrombotic (blood-clotting) disorders all under one roof.

25 Feb 2010

Institute of Medicine to be congratulated for calling more resources to fight hypertension

The Institute of Medicine is to be congratulated for sounding the call for more resources to fight hypertension (high blood pressure), the number two preventable cause of death and a leading contributor to heart disease and stroke. Heart disease and stroke are the number one and three overall causes of death of individuals in the United States.

25 Feb 2010

Nearly 40% of TIA and minor ischemic stroke patients may experience mental impairment

Nearly four in 10 transient ischemic attack (TIA) and minor ischemic stroke patients may experience mental impairment, according to a study presented at the American Stroke Association's International Stroke Conference 2010.

25 Feb 2010

Study examines associations of different fats and subtypes of ischemic stroke in post-menopausal women

Post-menopausal women who reported consuming the most daily dietary fat had a 40 percent higher incidence of clot-caused strokes compared to women who ate the least amount, according to research presented at the American Stroke Association's International Stroke Conference 2010.

25 Feb 2010

Study: Single, unhappily married men may have elevated risk of fatal stroke in the coming decades

Single or unhappily married men may have an elevated risk of fatal stroke in the coming decades, according to a large study presented at the American Stroke Association's International Stroke Conference 2010.

25 Feb 2010

More young people are having strokes while older people are having fewer: Study

More young people are having strokes while older people are having fewer, according to data from Ohio and Kentucky presented at the American Stroke Association's International Stroke Conference 2010.

25 Feb 2010

Shire receives FDA Fast Track designation for REPLAGAL

Shire plc, the global specialty biopharmaceutical company, announces it has received Fast Track designation from the FDA for REPLAGAL(R) (agalsidase alfa), its enzyme replacement therapy for Fabry disease.

24 Feb 2010

Incidence rate for all causes of dementia in older people to increase with age: Study

University of California researchers found that the incidence rate for all causes of dementia in people age 90 and older is 18.2% annually and significantly increases with age in both men and women. This research, called "The 90+ Study," is one of only a few to examine dementia in this age group, and the first to have sufficient participation of centenarians.

24 Feb 2010

QR Pharma awarded patent covering use of Posiphen and analogs in treatment of DS

QR Pharma, Inc., a developer of novel drugs to treat Alzheimer’s disease (AD), announced today that it was issued U.S. Patent No. 7,625,942, a "Method of Treating Down Syndrome" by the U.S. Patent and Trademark Office. The '942 patent covers use of Posiphen and analogs to treat cognitive impairments associated with Down Syndrome (DS). This patent valuably expands upon the original Posiphen and analog patent that claims composition of matter and use of compounds to lower amyloid-β precursor protein (APP) and thereby treat dementia and Alzheimer’s disease (AD).

24 Feb 2010

Guardian offers six questions to help employees and their families avoid critical illness

If you want to protect your finances from the costs of heart disease, and keep your heart healthy, the experts at The Guardian Life Insurance Company of America, a leading provider of employee benefits, have compiled important questions that you should ask yourself before American Heart Month ends.

24 Feb 2010

HealthGrades names Good Samaritan Hospital as One of America’s 50 Best Hospitals in 2010

Good Samaritan Hospital in Los Angeles is named as One of America’s 50 Best Hospitals in 2010 by HealthGrades, Inc., the nation’s leading independent healthcare ratings organization.

24 Feb 2010

BioMedix Vascular Solutions, Howard University Hospital partner to help uninsured PAD patients

BioMedix Vascular Solutions, Inc. announced today that the company has partnered with Howard University Hospital, Department of Surgery to participate in a Community Health Project and Demonstration focused on diagnosing and treating the potentially life-threatening condition called Peripheral Arterial Disease (PAD).

24 Feb 2010

Take 2 To Save 2 campaign: To send life-changing health messages to those who may be at risk for stroke

The American Stroke Association, a division of the American Heart Association, today launched a campaign that provides people an array of life-changing health messages to send to those who may be at risk for stroke.

24 Feb 2010

Joint science advisory issues messages for diabetics at risk for heart disease and stroke

The data are inconclusive on heart risks from a class of blood sugar-lowering drugs called thiazolidinediones (TZDs) such as pioglitazone (Actos) or rosiglitazone (Avandia), but the medications should be used with close monitoring from healthcare providers according to a joint science advisory from the American College of Cardiology and the American Heart Association.

24 Feb 2010

Medical innovation: A real boon for American patients

An article in the Journal Miner recently highlighted the fact that many people are living longer, healthier and more productive lives thanks to medical innovation and research.

24 Feb 2010

A1C lab test can help in combating diabetes

Approximately 57 million Americans are on the brink of diabetes. Yet research tells us that there is much we can do to keep it from progressing to full-blown diabetes. Lab tests can help us get a grip on the disease, says the American Clinical Laboratory Association President Alan Mertz.

24 Feb 2010

Woman's risk of heart disease intensifies during natural menopause: Study

When women hear the word menopause, they often think about hot flashes, hormone shifts and mood swings. But what about heart disease? Studies show a woman's risk of heart disease intensifies drastically around the time of natural menopause, which for most women is around the age of 50.

24 Feb 2010

OUTCOME, REACH Call partner to integrate stroke-telemedicine data into Get With The Guidelines–Stroke program

Outcome Sciences, Inc., the leading provider of patient registries, studies, and technologies for evaluating real-world outcomes, and REACH Call, the leading provider of web-based telemedicine services, today announced a partnership to integrate stroke-telemedicine data into the American Heart Association’s Get With The Guidelines®–Stroke program.

23 Feb 2010

Genentech's Avastin combination Phase III study in advanced stomach cancer does not meet primary endpoint

Genentech, Inc., a wholly owned member of the Roche Group, today announced that a Phase III study (AVAGAST) did not meet its primary endpoint of showing Avastin® (bevacizumab) plus Xeloda® (capecitabine) or 5-FU and cisplatin chemotherapy extended the lives of people with inoperable or advanced stomach (gastric) cancer, compared to chemotherapy alone.

23 Feb 2010

Stroke News and Research

Further Reading

Advanced ovarian cancer: Avastin-chemotherapy combination followed by Avastin alone improves PFS

JVC offers treatment for vascular diseases and thrombotic disorders under one roof

Institute of Medicine to be congratulated for calling more resources to fight hypertension

Nearly 40% of TIA and minor ischemic stroke patients may experience mental impairment

Study examines associations of different fats and subtypes of ischemic stroke in post-menopausal women

Study: Single, unhappily married men may have elevated risk of fatal stroke in the coming decades

More young people are having strokes while older people are having fewer: Study

Shire receives FDA Fast Track designation for REPLAGAL

Incidence rate for all causes of dementia in older people to increase with age: Study

QR Pharma awarded patent covering use of Posiphen and analogs in treatment of DS

Guardian offers six questions to help employees and their families avoid critical illness

HealthGrades names Good Samaritan Hospital as One of America’s 50 Best Hospitals in 2010

BioMedix Vascular Solutions, Howard University Hospital partner to help uninsured PAD patients

Take 2 To Save 2 campaign: To send life-changing health messages to those who may be at risk for stroke

Joint science advisory issues messages for diabetics at risk for heart disease and stroke

Medical innovation: A real boon for American patients

A1C lab test can help in combating diabetes

Woman's risk of heart disease intensifies during natural menopause: Study

OUTCOME, REACH Call partner to integrate stroke-telemedicine data into Get With The Guidelines–Stroke program

Genentech's Avastin combination Phase III study in advanced stomach cancer does not meet primary endpoint

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Expanding access to NMR with the Fourier 80 Duo

Latest News